HMGB1: An overview of its roles in the pathogenesis of liver disease

被引:48
作者
Ni, Yuan-Ao [1 ]
Chen, Hui [1 ]
Nie, Hao [1 ,2 ]
Zheng, Bing [1 ,2 ]
Gong, Quan [1 ,2 ]
机构
[1] Yangtze Univ, Sch Med, Dept Immunol, Jingzhou 434023, Hubei, Peoples R China
[2] Yangtze Univ, Sch Med, Clin Mol Immunol Ctr, Jingzhou, Hubei, Peoples R China
关键词
HMGB1; liver disease; RAGE; TLRs; signaling pathway; GROUP BOX 1; HEPATIC ISCHEMIA/REPERFUSION INJURY; ISCHEMIA-REPERFUSION INJURY; NUCLEAR FACTOR HMGB1; MOBILITY GROUP BOX-1; REGULATORY T-CELLS; RECEPTOR; FATTY LIVER; POSTTRANSLATIONAL MODIFICATIONS; MECHANISTIC BIOMARKERS;
D O I
10.1002/JLB.3MR0121-277R
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
High-mobility group box 1 (HMGB1) is an abundant architectural chromosomal protein that has multiple biologic functions: gene transcription, DNA replication, DNA-damage repair, and cell signaling for inflammation. HMGB1 can be released passively by necrotic cells or secreted actively by activated immune cells into the extracellular milieu after injury. Extracellular HMGB1 acts as a damage-associated molecular pattern to initiate the innate inflammatory response to infection and injury by communicating with neighboring cells through binding to specific cell-surface receptors, including Toll-like receptors (TLRs) and the receptor for advanced glycation end products (RAGE). Numerous studies have suggested HMGB1 to act as a key protein mediating the pathogenesis of chronic and acute liver diseases, including nonalcoholic fatty liver disease, hepatocellular carcinoma, and hepatic ischemia/reperfusion injury. Here, we provide a detailed review that focuses on the role of HMGB1 and HMGB1-mediated inflammatory signaling pathways in the pathogenesis of liver diseases.
引用
收藏
页码:987 / 998
页数:12
相关论文
共 153 条
  • [1] Acute Pancreatitis-Progress and Challenges A Report on an International Symposium
    Afghani, Elham
    Pandol, Stephen J.
    Shimosegawa, Tooru
    Sutton, Robert
    Wu, Bechien U.
    Vege, Santhi Swaroop
    Gorelick, Fred
    Hirota, Morihisa
    Windsor, John
    Lo, Simon K.
    Freeman, Martin L.
    Lerch, Markus M.
    Tsuji, Yoshihisa
    Melmed, Gil Y.
    Wassef, Wahid
    Mayerle, Julia
    [J]. PANCREAS, 2015, 44 (08) : 1195 - 1210
  • [2] Is HMGB1 a New Indirect Marker for Revealing Fibrosis in Chronic Hepatitis and a New Therapeutic Target in Treatment?
    Albayrak, Ayse
    Uyanik, Muhammet H.
    Cerrah, Serkan
    Altas, Sare
    Dursun, Hakan
    Demir, Mehmet
    Uslu, Hakan
    [J]. VIRAL IMMUNOLOGY, 2010, 23 (06) : 633 - 638
  • [3] Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease
    Alisi, Anna
    Nobili, Valerio
    Ceccarelli, Sara
    Panera, Nadia
    De Stefanis, Cristiano
    De Vito, Rita
    Vitali, Roberta
    Bedogni, Giorgio
    Balsano, Clara
    Cucchiara, Salvatore
    Stronati, Laura
    [J]. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2014, 14 (06) : 763 - 771
  • [4] The functions of HMGB1 depend on molecular localization and post-translational modifications Introduction
    Andersson, U.
    Antoine, D. J.
    Tracey, K. J.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2014, 276 (05) : 420 - 424
  • [5] Introduction: HMGB1 in inflammation and innate immunity
    Andersson, U.
    Rauvala, H.
    [J]. JOURNAL OF INTERNAL MEDICINE, 2011, 270 (04) : 296 - 300
  • [6] Clinical Implication of the Relationship Between High Mobility Group Box-1 and Tumor Differentiation in Hepatocellular Carcinoma
    Ando, Kei
    Sakoda, Masahiko
    Ueno, Shinichi
    Hiwatashi, Kiyokazu
    Iino, Satoshi
    Minami, Koji
    Kawasaki, Yota
    Hashiguchi, Motoyuki
    Tanoue, Kiyonori
    Mataki, Yuko
    Kurahara, Hiroshi
    Maemura, Kosei
    Shinchi, Hiroyuki
    Natsugoe, Shoji
    [J]. ANTICANCER RESEARCH, 2018, 38 (06) : 3411 - 3418
  • [7] Mechanistic biomarkers provide early and sensitive detection of acetaminophen-induced acute liver injury at first presentation to hospital
    Antoine, Daniel J.
    Dear, James W.
    Lewis, Philip Starkey
    Platt, Vivien
    Coyle, Judy
    Masson, Moyra
    Thanacoody, Ruben H.
    Gray, Alasdair J.
    Webb, David J.
    Moggs, Jonathan G.
    Bateman, D. Nicholas
    Goldring, Christopher E.
    Park, B. Kevin
    [J]. HEPATOLOGY, 2013, 58 (02) : 777 - 787
  • [8] RETRACTED: Molecular forms of HMGB1 and keratin-18 as mechanistic biomarkers for mode of cell death and prognosis during clinical acetaminophen hepatotoxicity (Publication with Expression of Concern. See vol. 73, pg. 1297, 2020) (Publication with Expression of Concern. See vol. 69, pg. 1402, 2018) (Retracted article. See vol. 73, pg. 1297, 2020)
    Antoine, Daniel J.
    Jenkins, Rosalind E.
    Dear, James W.
    Williams, Dominic P.
    McGill, Mitchell R.
    Sharpe, Matthew R.
    Craig, Darren G.
    Simpson, Kenneth J.
    Jaeschke, Hartmut
    Park, B. Kevin
    [J]. JOURNAL OF HEPATOLOGY, 2012, 56 (05) : 1070 - 1079
  • [9] The importance of immune dysfunction in determining outcome in acute liver failure
    Antoniades, Charalambos Gustav
    Berry, Philip A.
    Wendon, Julia A.
    Vergani, Diego
    [J]. JOURNAL OF HEPATOLOGY, 2008, 49 (05) : 845 - 861
  • [10] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    Apetoh, Lionel
    Ghiringhelli, Francois
    Tesniere, Antoine
    Obeid, Michel
    Ortiz, Carla
    Criollo, Alfredo
    Mignot, Gregoire
    Maiuri, M. Chiara
    Ullrich, Evelyn
    Saulnier, Patrick
    Yang, Huan
    Amigorena, Sebastian
    Ryffel, Bernard
    Barrat, Franck J.
    Saftig, Paul
    Levi, Francis
    Lidereau, Rosette
    Nogues, Catherine
    Mira, Jean-Paul
    Chompret, Agnes
    Joulin, Virginie
    Clavel-Chapelon, Francoise
    Bourhis, Jean
    Andre, Fabrice
    Delaloge, Suzette
    Tursz, Thomas
    Kroemer, Guido
    Zitvogel, Laurence
    [J]. NATURE MEDICINE, 2007, 13 (09) : 1050 - 1059